131-I-MIBG therapy in combination with PARP inhibitors for young adult patient with relapsed neuroblastoma and DNA repair pathway alterations

• Sarah Cohen-Gogo,
• Amer Shammas,
• Adam Shlien,
• Meredith Irwin,
• Daniel Morgenstern

Affiliations

Sarah Cohen-Gogo

Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada; Genetics and Genome Biology, The Hospital for Sick Children Research Institute, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada; Corresponding author at: Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.

Amer Shammas

Division of Nuclear Medicine, Department of Diagnostic Imaging, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada

Adam Shlien

Genetics and Genome Biology, The Hospital for Sick Children Research Institute, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada; Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada

Meredith Irwin

Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada; Department of Pediatrics, University of Toronto, 27 King's College Circle, Toronto, Ontario M5S 1A1, Canada

Daniel Morgenstern

Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada; Department of Pediatrics, University of Toronto, 27 King's College Circle, Toronto, Ontario M5S 1A1, Canada